

**CONTACT - Media:**

Amsterdam	+31.20.550.4488	Brussels	+32.2.509.1392
Lisbon	+351.217.900.029	London	+44.20.7379.2789
New York	+1.212.656.2411	Paris	+33.1.49.27.11.33

**CONTACT - Investor Relations:**

New York +1.212.656.5700

**nyx.com**

Please follow us at:  
[Exchanges Blog](#)  
[Facebook](#)  
[LinkedIn](#)  
[Twitter](#)

**NYSE Euronext Announces Trading Volumes for December 2012 and Other Metrics**  
*Global Derivatives ADV of 7.5 Million Contracts in December In-line with Prior Year*  
*NYSE Liffe Fixed Income Products ADV Up 17% Versus Prior Year*  
*European and U.S. Cash Equities ADV Lower*

**January 10, 2013** – NYSE Euronext (NYX) today announced trading volumes for its global derivatives and cash equities exchanges for December 2012<sup>1</sup>. Global derivatives average daily volume (“ADV”) of 7.5 million contracts in December 2012 was down slightly compared to December 2011 and decreased 8.0% from November 2012 levels on seasonally slower trading activity. European derivatives fixed income ADV, however, increased 17.4% from December 2011 levels. Trading volumes in European and U.S. equities, declined both year-over-year and month-over-month.

**Highlights**

- NYSE Euronext global derivatives ADV in December 2012 of 7.5 million contracts decreased 0.2% compared to December 2011, and decreased 8.0% from November 2012 levels.
- NYSE Euronext European derivatives products ADV in December 2012 of 3.5 million contracts increased 1.5% compared to December 2011, but decreased 12.4% from November 2012 levels. Excluding Bclear, NYSE Liffe's trade administration and clearing service for OTC products, European derivatives products ADV increased 8.5% compared to December 2011 and increased 1.5% from November 2012.
- NYSE Euronext U.S. equity options (NYSE Arca and NYSE Amex Options) ADV of 3.9 million contracts in December 2012 decreased 1.2% compared to December 2011 levels, and decreased by 4.4% from November 2012 levels. NYSE Euronext's U.S. options exchanges accounted for 27.2% of total U.S. consolidated equity options trading in December 2012, down from 27.7% in December 2011 and down from 28.1% in November 2012.
- NYSE Liffe U.S. ADV of approximately 72,600 contracts decreased from 89,600 contracts in December 2011, but increased from 51,500 contracts in November 2012.
- NYSE Euronext European cash products ADV of 1.1 million transactions in December 2012 decreased 20.2% compared to December 2011 and decreased 8.7% compared to November 2012.

---

<sup>1</sup> All NYSE Euronext derivatives transactions count buy and sell orders together as a single transaction. NYSE Euronext European equities transactions count each buy and sell order as separate transactions, NYSE Euronext U.S. equities transactions count buy and sell orders together as a single transaction.

- NYSE Euronext U.S. cash products (NYSE, NYSE Arca and NYSE-MKT) handled ADV of 1.5 billion shares in December 2012 decreased 14.7% compared to December 2011 and decreased 3.4% compared to November 2012. NYSE Euronext's Tape A matched market share in December 2012 was 31.9%, down from 33.4% in December 2011, but up from 31.7% in November 2012.
- The preliminary average net revenue per transaction type (as defined below) for each of the primary trading venues in the fourth quarter of 2012 is included below:

Trading Venue	Preliminary		
	4Q11	3Q12	4Q12
European Derivatives (ex. Bclear) <sup>1</sup>	\$0.698	\$0.657	\$0.67
U.S. Derivatives <sup>2</sup>	\$0.148	\$0.144	\$0.14
European Cash <sup>3</sup>	\$0.582	\$0.537	\$0.58
U.S. Cash <sup>4</sup>	\$0.039	\$0.040	\$0.040

<sup>1</sup> Average net revenue per contract, excluding Bclear.

<sup>2</sup> Average net revenue per contract. Excludes NYSE Liffe U.S. trading volume.

<sup>3</sup> Average net revenue per transaction.

<sup>4</sup> Average net revenue per 100 shares handled.

## Derivatives Trading

### European Derivatives

- NYSE Euronext European derivatives products ADV in December 2012 was 3.5 million futures and options contracts, an increase of 1.5% from December 2011, but a decrease of 12.4% from November 2012.
- The 3.5 million in European derivatives futures and options contracts ADV in December 2012 consisted of 2.4 million contracts executed through our full-service LIFFE CONNECT trading platform and 1.1 million contracts, or 31.6%, executed through Bclear, NYSE Liffe's trade administration and clearing service for OTC products. Excluding Bclear, European derivatives products ADV increased 8.5% compared to December 2011 and increased 1.5% from November 2012.
- In the fourth quarter of 2012, European derivatives products ADV of 3.5 million contracts was 2.3% below prior year levels. The 3.5 million in futures and options contracts ADV in the fourth quarter of 2012 consisted of 2.3 million contracts executed through LIFFE CONNECT trading platform and 1.2 million contracts, or 33.7%, executed through Bclear.
- For the full-year 2012, European derivatives products ADV of 3.7 million contracts was 16.8% below prior year levels. The 3.7 million in futures and options contracts ADV year-to-date consisted of 2.6 million contracts executed through LIFFE CONNECT trading platform and 1.1 million contracts, or 29.7%, executed through Bclear.
- Total fixed income products ADV of 1.6 million contracts in December 2012 increased 17.4% from December 2011 and increased 0.3% from November 2012. In the fourth quarter of 2012, total fixed income products ADV of 1.6 million contracts was 13.3% below prior year levels. For the full-year 2012, total fixed income products ADV of 1.8 million contracts was 22.0% below prior year levels.
- Total equity products (including Bclear) ADV of 1.8 million contracts in December 2012 decreased 10.6% compared to December 2011 and decreased 21.9% from November 2012. The 1.8 million contracts in equity products ADV consisted of 1.3

million contracts in individual equity products ADV and 0.5 million contracts in equity index products ADV. The 1.3 million contracts in individual equity products ADV consisted of 0.9 million in futures contracts, which represented a 14.0% decrease compared to December 2011 and 0.4 million in options contracts, which represented a 17.9% decrease compared to December 2011. In the fourth quarter of 2012, total equity products ADV of 1.9 million contracts were 7.6% below prior year levels. For the full-year 2012, total equity products ADV of 1.9 million contracts were 12.3% below prior year levels.

- Total commodities products ADV of 97,000 contracts in December 2012 increased 43.3% compared to December 2011 and increased 12.5% compared to November 2012. In the fourth quarter of 2012, total commodities product ADV of 96,500 contracts was 34.3% above prior year levels. For the full-year 2012, total commodities product ADV of 89,000 contracts was 10.6% above prior year levels.

#### *U.S. Derivatives*

- NYSE Euronext U.S. equity options (NYSE Arca and NYSE Amex Options) ADV of 3.9 million contracts in December 2012 decreased 1.2% compared to December 2011 and decreased 4.4% compared to November 2012. In the fourth quarter of 2012, U.S. equity options ADV of 4.0 million contracts was 6.7% below prior year levels. For the full-year 2012, U.S. equity options ADV of 3.9 million contracts was 11.6% below prior year levels.
- Total U.S. consolidated equity options ADV increased 0.4% to 14.3 million contracts in December 2012 compared to December 2011, but decreased 1.5% compared to November 2012. In the fourth quarter of 2012, U.S. consolidated equity options ADV of 14.3 million contracts was 7.6% below prior year levels. For the full-year 2012, U.S. consolidated equity options ADV of 14.7 million contracts was 12.2% below prior year levels.
- NYSE Euronext's U.S. options exchanges accounted for 27.2% of the total U.S. consolidated equity options trading in December 2012, down from 27.7% in December 2011 and down slightly from a record 28.1% in November 2012.
- NYSE Liffe U.S. ADV of approximately 72,600 contracts decreased from 89,600 contracts in December 2011, but increased from 51,500 contracts in November 2012. In December 2012, the mini MSCI Index futures traded a record ADV of 41,570 contracts, an increase of 108% compared to December 2011, and open interest across the entire MSCI complex hit an all time high on December 19, 2012 of 267,932 contracts. In the fourth quarter of 2012, U.S. futures and futures options ADV of 55,200 contracts was 39.4% below prior year levels. For the full-year 2012, U.S. futures and futures options ADV of 72,700 contracts was 10.4% below prior year levels.

#### **Cash Trading**

##### *European Cash*

- NYSE Euronext European cash products ADV of 1.1 million transactions in December 2012 decreased 20.2% compared to December 2011 and decreased 8.7% compared to November 2012.
- NYSE Euronext market share in European Cash products in December 2012 was 68.7%, up from 66.0% in December 2011 and up from 64.9% in November 2012.
- In the fourth quarter of 2012, European cash products market share was 66.5% with ADV of 1.2 million transactions which was 25.6% below prior year levels.

- For the full-year 2012, European cash products market share was 66.2% with ADV of 1.4 million transactions which was 15.5% below prior year levels.

#### *U.S. Cash*

- NYSE Euronext U.S. cash products handled ADV in December 2012 decreased 14.7% to 1.5 billion shares compared to December 2011 and decreased 3.4% from November 2012.
- In the fourth quarter of 2012, U.S. cash products handled ADV was 1.6 billion shares, down 27.3% from prior year levels.
- For the full-year 2012, U.S. cash products handled ADV was 1.7 billion shares, down 26.2% from prior year levels.
- NYSE Euronext's Tape A matched market share in December 2012 was 31.9%, down from 33.4% in December 2011, but up from 31.7% in November 2012.

#### *Exchange Traded Funds*

- NYSE Euronext U.S. matched exchange-traded funds ADV (included in volumes for Tape B and Tape C) of 193 million shares in December 2012 decreased 22.1% compared to December 2011 and decreased 7.5% compared to November 2012.
- In the fourth quarter of 2012, NYSE Euronext U.S. matched exchange-traded funds ADV of 197 million shares was 38.9% below prior year levels.
- For the full-year 2012, NYSE Euronext U.S. matched exchange-traded funds ADV of 211 million shares was 34.9% below prior year levels.

#### **Other Metrics**

- On October 5, 2012, NYSE Euronext closed on the public offering of \$850 million 2.00% notes due in October 2017. The proceeds from this offering were used to fund the purchase of \$336 million of our outstanding \$750 million 4.80% notes due in June 2013 and €80 million of our €1 billion 5.375% notes due in June 2015 and for other general corporate purposes, including the reduction in outstanding commercial paper. As a result of the refinancing, interest expense is expected to decline by approximately \$1 million in the fourth quarter of 2012, excluding a \$24 million one-time charge for the refinancing which will be excluded from fourth quarter 2012 non-GAAP financial results. The refinancing is expected to save an annualized \$15 million and \$24 million in interest expense in 2013 and 2014, respectively.
- The average EUR/USD exchange rate for the fourth quarter of 2012 of \$1.30 represented an increase of 3.7% from the third quarter of 2012 and a decrease of 3.8% compared to the fourth quarter of 2011. The average GBP/USD exchange rate for the fourth quarter of 2012 of \$1.61 represented an increase of 1.6% from the third quarter of 2012 and an increase of 2.1% compared to the fourth quarter of 2011.
- During the fourth quarter of 2012, a total of 1.1 million shares were repurchased at an average price of \$24.67. As a result of these repurchases, the weighted average diluted shares outstanding in the fourth quarter of 2012 was 245 million shares.

Please [click here](#) for the Monthly Transaction Activity Data Table.

#### **About NYSE Euronext**

NYSE Euronext (NYX) is a leading global operator of financial markets and provider of innovative trading technologies. The company's exchanges in Europe and the United States trade equities, futures, options, fixed-income and exchange-traded products. With approximately 8,000 listed issues (excluding European Structured Products), NYSE Euronext's

equities markets - the New York Stock Exchange, NYSE Euronext, NYSE MKT, NYSE Alternext and NYSE Arca - represent one-third of the world's equities trading, the most liquidity of any global exchange group. NYSE Euronext also operates NYSE Liffe, one of the leading European derivatives businesses and the world's second-largest derivatives business by value of trading. The company offers comprehensive commercial technology, connectivity and market data products and services through NYSE Technologies. NYSE Euronext is in the S&P 500 index. For more information, please visit: <http://www.nyx.com>.

### **Forward-Looking Statements**

This press release may contain “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by words such as “may,” “hope,” “will,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential,” “continue,” “could,” “future” or the negative of those terms or other words of similar meaning. You should carefully read forward-looking statements, including statements that contain these words, because they discuss our future expectations or state other “forward-looking” information. Forward-looking statements involve a number of risks and uncertainties. ICE and NYSE Euronext caution readers that any forward-looking statement is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking statement. Such forward-looking statements include, but are not limited to, statements about the benefits of the proposed merger involving ICE and NYSE Euronext, including future financial results, ICE’s and NYSE Euronext’s plans, objectives, expectations and intentions, the expected timing of completion of the transaction and other statements that are not historical facts. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in ICE’s and NYSE Euronext’s filings with the U.S. Securities and Exchange Commission (the “SEC”). These risks and uncertainties include, without limitation, the following: the inability to close the merger in a timely manner; the inability to complete the merger due to the failure of NYSE Euronext stockholders to adopt the merger agreement or the failure of ICE stockholders to approve the issuance of ICE common stock in connection with the merger; the failure to satisfy other conditions to completion of the merger, including receipt of required regulatory and other approvals; the failure of the proposed transaction to close for any other reason; the possibility that any of the anticipated benefits of the proposed transaction will not be realized; the risk that integration of NYSE Euronext’s operations with those of ICE will be materially delayed or will be more costly or difficult than expected; the challenges of integrating and retaining key employees; the effect of the announcement of the transaction on ICE’s, NYSE Euronext’s or the combined company’s respective business relationships, operating results and business generally; the possibility that the anticipated synergies and cost savings of the merger will not be realized, or will not be realized within the expected time period; the possibility that the merger may be more expensive to complete than anticipated, including as a result of unexpected factors or events; diversion of management’s attention from ongoing business operations and opportunities; general competitive, economic, political and market conditions and fluctuations; actions taken or conditions imposed by the United States and foreign governments and regulatory authorities; and adverse outcomes of pending or threatened litigation or government investigations. In addition, you should carefully consider the risks and uncertainties and other factors that may affect future results of the combined company described in the section entitled “Risk Factors” in the joint proxy statement/prospectus to be delivered to ICE’s and NYSE Euronext’s respective shareholders, and in ICE’s and NYSE Euronext’s respective filings with the SEC that are available on the SEC’s web site located at [www.sec.gov](http://www.sec.gov), including the sections entitled “Risk Factors” in ICE’s Form 10-K for the fiscal year ended December 31,

2011, as filed with the SEC on February 8, 2012, and ICE's Quarterly Reports on Form 10-Q for the quarters ended June 30, 2012, as filed with the SEC on August 1, 2012 and September 30, 2012, as filed with the SEC on November 5, 2012, and "Risk Factors" in NYSE Euronext's Form 10-K for the fiscal year ended December 31, 2011, as filed with the SEC on February 29, 2012. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release. Except for any obligations to disclose material information under the Federal securities laws, NYSE Euronext undertakes no obligation to publicly update any forward-looking statements to reflect events or circumstances after the date of this press release.

**Important Information About the Proposed Transaction and Where to Find It:**

In connection with the proposed transaction, ICE intends to file with the SEC a registration statement on Form S-4, which will include a joint proxy statement/prospectus with respect to the proposed acquisition of NYSE Euronext. The final joint proxy statement/prospectus will be delivered to the stockholders of ICE and NYSE Euronext. Investors and security holders of both ICE and NYSE Euronext are urged to read the joint proxy statement/prospectus regarding the proposed transaction carefully and in its entirety, including any documents previously filed with the SEC and incorporated by reference into the joint proxy statement/prospectus, when it becomes available because it will contain important information regarding ICE, NYSE Euronext and the proposed merger. Investors will be able to obtain a free copy of the joint proxy statement/prospectus, as well as other filings containing information about ICE and NYSE Euronext, without charge, at the SEC's website at <http://www.sec.gov/>. Investors may also obtain these documents, without charge, from ICE's website at <http://www.theice.com>.

**Participants in the Merger Solicitation:**

ICE, NYSE Euronext and their respective directors, executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies in respect of the transactions contemplated by the merger agreement.

You can find information about ICE and ICE's directors and executive officers in ICE's Annual Report on Form 10-K for the year ended December 31, 2011, as filed with the SEC on February 8, 2012, and ICE's proxy statement for its 2012 annual meeting of stockholders, as filed with the SEC on March 30, 2012.

You can find information about NYSE Euronext and NYSE Euronext's directors and executive officers in NYSE Euronext's Annual Report on Form 10-K for the year ended December 31, 2011, as filed with the SEC on February 29, 2012, and NYSE Euronext's proxy statement for its 2012 annual meeting of stockholders, filed with the SEC on March 26, 2012.

Additional information about the interests of potential participants will be included in the joint proxy statement/prospectuses, if and when it becomes available, and the other relevant documents filed by ICE and NYSE Euronext with the SEC.

This announcement does not constitute and offer or any solicitation of any offer, to buy or subscribe for any securities.

**NYSE Euronext  
Monthly Volume Summary**

	Average Daily Volume			Total Volume			Average Daily Volume		Total Volume	
	déc-12	déc-11	% Chg	déc-12	déc-11	% Chg	YTD 2012	YTD 2011	YTD 2012	YTD 2011
(Unaudited; contracts in thousands)										
Number of Trading Days - European Cash	19	21		19	21		256		256	
Number of Trading Days - European Derivatives	19	21		19	21		257		257	
Number of Trading Days - U.S. Markets	20	21		20	21		250		250	
<b>European Derivatives Products</b>	<b>3 491</b>	<b>3 440</b>	<b>1,5%</b>	<b>66 326</b>	<b>72 245</b>	<b>-8,2%</b>	<b>3 719</b>	<b>-16,8%</b>	<b>955 802</b>	<b>-16,8%</b>
<i>of which Bclear</i>	1 103	1 240	-11,1%	20 949	26 046	-19,6%	1 103	-3,3%	283 554	-3,3%
<b>Total Fixed Income Products</b>	<b>1 587</b>	<b>1 352</b>	<b>17,4%</b>	<b>30 146</b>	<b>28 390</b>	<b>6,2%</b>	<b>1 754</b>	<b>-22,0%</b>	<b>450 896</b>	<b>-22,0%</b>
Short Term Interest Rate Products	1 468	1 268	15,8%	27 897	26 625	4,8%	1 602	-24,1%	411 806	-24,1%
Medium and Long Term Interest Rate Products <sup>1</sup>	118	84	40,8%	2 249	1 766	27,4%	152	9,5%	39 089	9,5%
<b>Total Equity Products<sup>2</sup></b>	<b>1 807</b>	<b>2 021</b>	<b>-10,6%</b>	<b>34 335</b>	<b>42 432</b>	<b>-19,1%</b>	<b>1 875</b>	<b>-12,3%</b>	<b>481 969</b>	<b>-12,3%</b>
Individual Equity Products	1 296	1 529	-15,2%	24 626	32 109	-23,3%	1 398	-10,4%	359 382	-10,4%
Futures	907	1 056	-14,0%	17 241	22 168	-22,2%	959	-1,6%	246 542	-1,6%
Options	389	473	-17,9%	7 385	9 941	-25,7%	439	-25,1%	112 841	-25,1%
Equity Index Products	511	492	3,9%	9 709	10 323	-6,0%	477	-17,5%	122 587	-17,5%
<i>of which Bclear</i>	1 103	1 240	-11,1%	20 949	26 046	-19,6%	1 103	-3,3%	283 554	-3,3%
Individual Equity Products	983	1 142	-14,0%	18 671	23 986	-22,2%	1 027	-3,1%	263 840	-3,1%
Futures	907	1 055	-14,0%	17 241	22 165	-22,2%	938	-2,2%	240 967	-2,2%
Options	75	87	-13,2%	1 430	1 820	-21,4%	89	-11,9%	22 873	-11,9%
Equity Index Products	120	98	22,2%	2 278	2 060	10,6%	77	-5,5%	19 714	-5,5%
<b>Commodity Products</b>	<b>97</b>	<b>68</b>	<b>43,3%</b>	<b>1 844</b>	<b>1 422</b>	<b>29,7%</b>	<b>89</b>	<b>10,6%</b>	<b>22 937</b>	<b>10,6%</b>
<b>U.S. Derivatives Products</b>										
<b>Equity Options<sup>3</sup></b>										
NYSE Euronext Options Contracts	3 888	3 936	-1,2%	77 767	82 656	-5,9%	3 893	-11,6%	973 140	-12,3%
Total Consolidated Options Contracts	14 275	14 224	0,4%	285 492	298 702	-4,4%	14 727	-12,2%	3 681 821	-12,8%
NYSE Group Share of Total	27,2%	27,7%		27,2%	27,7%		26,4%	0,1%	26,4%	0,1%
<b>NYSE Liffe U.S.</b>										
Futures and Futures Options Volume <sup>4</sup>	72,6	89,6	-19,0%	1 452	1 882	-22,8%	72,7	-10,4%	18 769,2	-10,4%
<b>European Cash Products (trades in thousands)</b>	<b>1 068</b>	<b>1 338</b>	<b>-20,2%</b>	<b>20 297</b>	<b>28 095</b>	<b>-27,8%</b>	<b>1 445</b>	<b>-15,5%</b>	<b>370 013</b>	<b>-15,9%</b>
Equities	1 026	1 287	-20,2%	19 503	27 023	-27,8%	1 396	-15,1%	357 365	-15,4%
Exchange-Traded Funds	12	15	-25,0%	221	325	-32,1%	13	-35,0%	3 412	-35,2%
Structured Products	24	31	-20,9%	459	642	-28,4%	31	-25,7%	7 885	-26,0%
Bonds	6	5	20,5%	114	104	9,0%	5	5,8%	1 350	5,3%
<b>U.S. Cash Products (shares in millions)<sup>5</sup></b>	<b>1 531</b>	<b>1 794</b>	<b>-14,7%</b>	<b>30 623</b>	<b>37 682</b>	<b>-18,7%</b>	<b>1 685</b>	<b>-26,2%</b>	<b>421 338</b>	<b>-26,8%</b>
<b>NYSE Listed (Tape A) Issues<sup>4</sup></b>										
Handled Volume <sup>5</sup>	1 110	1 277	-13,1%	22 196	26 821	-17,2%	1 207	-24,9%	301 769	-25,5%
Matched Volume <sup>6</sup>	1 068	1 212	-11,8%	21 363	25 445	-16,0%	1 147	-24,7%	286 785	-25,3%
Total NYSE Listed Consolidated Volume	3 353	3 623	-7,4%	67 069	76 086	-11,9%	3 659	-16,3%	914 654	-16,9%
<b>Share of Total Consolidated Volume</b>										
Handled Volume <sup>5</sup>	33,1%	35,3%	-2,2%	33,1%	35,3%	-2,2%	33,0%	-3,8%	33,0%	-3,8%
Matched Volume <sup>6</sup>	31,9%	33,4%	-1,5%	31,9%	33,4%	-1,5%	31,4%	-3,5%	31,4%	-3,5%
<b>NYSE Arca, MKT and Regional (Tape B) Listed Issues</b>										
Handled Volume <sup>5</sup>	225	295	-23,7%	4 501	6 192	-27,3%	248	-35,0%	61 957	-35,5%
Matched Volume <sup>6</sup>	209	263	-20,6%	4 171	5 517	-24,4%	225	-34,6%	56 127	-35,1%
Total NYSE Arca & MKT Listed Consolidated Volume	970	1 170	-17,1%	19 403	24 580	-21,1%	1 055	-28,4%	263 832	-29,0%
<b>Share of Total Consolidated Volume</b>										
Handled Volume <sup>5</sup>	23,2%	25,2%	-2,0%	23,2%	25,2%	-2,0%	23,5%	-2,4%	23,5%	-2,4%
Matched Volume <sup>6</sup>	21,5%	22,4%	-0,9%	21,5%	22,4%	-0,9%	21,3%	-2,0%	21,3%	-2,0%
<b>Nasdaq Listed (Tape C) Issues</b>										
Handled Volume <sup>5</sup>	196	222	-11,7%	3 926	4 669	-15,9%	230	-21,8%	57 612	-22,4%
Matched Volume <sup>6</sup>	175	189	-7,5%	3 506	3 979	-11,9%	199	-21,6%	49 756	-22,2%
Total Nasdaq Listed Consolidated Volume	1 689	1 615	4,6%	33 776	33 911	-0,4%	1 749	-13,5%	437 168	-14,2%
<b>Share of Total Consolidated Volume</b>										
Handled Volume <sup>5</sup>	11,6%	13,8%	-2,2%	11,6%	13,8%	-2,2%	13,2%	-1,4%	13,2%	-1,4%
Matched Volume <sup>6</sup>	10,4%	11,7%	-1,3%	10,4%	11,7%	-1,3%	11,4%	-1,2%	11,4%	-1,2%
<b>Exchange-Traded Funds<sup>5,7</sup></b>										
Handled Volume <sup>5</sup>	208	279	-25,3%	4 166	5 854	-28,8%	233	-35,4%	58 195	-35,9%
Matched Volume <sup>6</sup>	193	248	-22,1%	3 858	5 202	-25,8%	211	-34,9%	52 682	-35,5%
Total ETF Consolidated Volume	929	1 139	-18,5%	18 575	23 917	-22,3%	1 020	-28,2%	255 004	-28,7%
<b>Share of Total Consolidated Volume</b>										
Handled Volume <sup>5</sup>	22,4%	24,5%	-2,1%	22,4%	24,5%	-2,1%	22,8%	-2,5%	22,8%	-2,5%
Matched Volume <sup>6</sup>	20,8%	21,7%	-0,9%	20,8%	21,7%	-0,9%	20,7%	-2,1%	20,7%	-2,1%

1 Data includes currency products.

2 Includes all trading activities for Bclear, NYSE Liffe's clearing service for wholesale derivatives.

3 Includes trading in U.S. equity options contracts, not equity-index options.

4 Includes all volume executed in NYSE Group crossing sessions.

5 Represents the total number of shares of equity securities and ETFs internally matched on the NYSE Group's exchanges or routed to and executed at an external market center. NYSE Arca routing includes odd-lots.

6 Represents the total number of shares of equity securities and ETFs executed on the NYSE Group's exchanges.

7 Data included in previously identified categories.

\* ADVs calculated with the appropriate number of NYSE Liffe U.S. trading days.

Source: NYSE Euronext, Options Clearing Corporation and Consolidated Tape as reported for equity securities.

All trading activity is single-counted, except European cash trading which is double counted to include both buys and sells.